|Bid||7.73 x 0|
|Ask||7.72 x 0|
|Day's Range||7.63 - 8.09|
|52 Week Range||3.70 - 9.29|
|Beta (3Y Monthly)||4.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.26|
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Aurora CannabisAurora Cannabis (ACB) has been almost flat since it reported its earnings on February 11. To learn more about the company’s earnings, read Aurora
Analysts' Ratings for ACB, CRON, and APHA in February(Continued from Prior Part)Cronos Group Cronos Group (CRON) hasn’t reported its earnings yet. Cronos Group has been one of the top choices for investors (HMMJ) along with Canopy Growth (WEED),
Canaccord Genuity Raises Price Target for Canopy GrowthCanaccord Genuity raises price targetOn February 18, Canopy Growth (WEED) received a price target upgrade from Canaccord Genuity after the company reported its Q3 earnings on February 14.
Over the last year, Canada approved its recreational use. Corporate America is using cannabinoids and hemp oil in everything from lotions and pain balm to beverages. President Trump signed the 2018 Farm Bill into law.
Key Takeaways from Canopy Growth's Q3 Earnings CallCanopy Growth’s earningsOn February 14, Canopy Growth (WEED) (CGC) reported its earnings. The company held an earnings call the next day. We discussed the earnings call and summarized the key
NYSE-A: HEXO) is pleased to announce it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce (“CIBC”), as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together with CIBC, the “Lenders”). Under the terms of the credit facility, the Lenders will provide HEXO up to C$65 million of secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range over its three-year term.
Analyzing Canopy Growth's Q3 Results(Continued from Prior Part)Margins During the third quarter, Canopy Growth (WEED) (CGC) reported a gross margin of ~12.4 million Canadian dollars, which was lower compared to 16.5 million Canadian dollars in the
Analysts' Ratings for WEED, TLRY, and APHA in February(Continued from Prior Part)Sales to grow Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. Canopy Growth is expected to see
Aurora Cannabis: Key Takeaways from Its Q2 Earnings(Continued from Prior Part)Gross margins fell In the second quarter, Aurora Cannabis (ACB) reported nearly 363% YoY (year-over-year) and 83% sequential sales growth. The company reported gross
Cannabis Stocks Hit Pause Last WeekWeekly performanceIn the week ending February 8, cannabis stocks ended in the red. The Horizons Marijuana Life Sciences ETF (HMMJ) fell nearly 2.8% from the closing on February 1. The Emerging Marijuana Growers
Do Cannabis Stocks Look Expensive?(Continued from Prior Part)Other cannabis companies Previously in this series, we compared four cannabis stocks’ forward EV-to-sales multiples. In this part, we’ll discuss the other five cannabis stocks.
What to Expect from Canopy Growth's Q3 EarningsCanopy Growth’s upcoming earnings Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. The company is one of the most valuable
Curaleaf Is Up ~40% in 2019: Is There More Upside?(Continued from Prior Part)Analysts’ recommendations Of the three analysts that cover Curaleaf Holdings (CURLF), two are favoring a “strong buy,” and one is favoring a “buy.” On average,
Why Analysts Expect Tilray to Report a Loss in the Fourth QuarterTilray to report earnings According to NASDAQ, Tilray (TLRY) is set to report its fourth-quarter earnings next week, on February 12. Let’s look at analysts’ expectations for the
With proponents claiming that it can treat ailments as diverse as inflammation, pain, cancer, insomnia, anxiety, and depression, it's no surprise that it's already impacting major industries, like the $4.2 trillion wellness market. In fact, CBD is already showing up in spa, wellness and skincare industry products. ''Hemp-derived CBD has been touted in several medical studies as having a myriad of health benefits ranging from treating psoriasis, atopic dermatitis and eczema to minimizing seizures, stress, and insomnia,'' notes Forbes.
Canopy Growth's Bruce Linton Talks Next Steps for the IndustryShedding lightLast week, Canopy Growth (WEED) (CGC) CEO Bruce Linton shed light on the next phases for the cannabis industry at the Cantech Investment Conference.These insights have
In fact, analysts at Cowen say U.S. cannabis sales alone could reach $80 billion by 2030 - an increase of $5 billion from earlier estimates, and a 4% compound annual growth rate. Piper Jaffray believes the market for legal cannabis could be worth $15 billion to $50 billion a year, with global sales growing to $250 billion to $500 billion. Corporate America is quickly waking up to the opportunity with alcohol companies taking a stake in cannabis stocks.
Mugglehead believes the cannabis industry will look very different a year from now. Meanwhile, with hemp-derived cannabidiol (CBD) now being permitted federally, the U.S. market could also see a whole new wave of cannabis products. One of the biggest stocks in the space, Tilray is looking to make a big splash in the beverages market.
Marijuana Legalization Gets Support from Presidential CandidatesCannabis industry As the world watched Canada legalize marijuana for recreational purposes in October, some critics thought that legalization was a mistake. Marijuana has often been
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in HEXO Corp. Read More...
Why Aphria Rose 13% on January 31(Continued from Prior Part)Green Growth’s offerGreen Growth’s offer came at a time when Aphria stock was being criticized by short sellers. Green Growth filed a formal offer this month to acquire all of
NYSE-A: HEXO) is pleased to announce the closing of its previously announced marketed offering of 8,855,000 common shares at a price of C$6.50 per share for aggregate gross proceeds of C$57,557,500, which includes the exercise of the full over-allotment option of 1,155,000 common shares. The Company will use the net proceeds from the Offering for general corporate purposes, including funding the Company’s global growth initiatives and research and development to further advance the Company’s innovation strategies.
Cannabis 2019: Comparing Jim Cramer's Views with Market Realist's(Continued from Prior Part)Continuing the listAmong Jim Cramer’s predictions for 2019, he included more brands and investors in the cannabis industry this year. Cramer believes that
How Is Cannabis Stock Kushco Holdings Positioned in January?Stock performanceOn January 29, Kushco Holdings closed at $5.5, ~0.55% higher than its prior day close, ~2% higher YTD, and a ~24% discount over its 52-week high of $7.2 on January 11,